All manuscripts
Publications Other T-Cells TIL Cells G-Rex®100 G-Rex®100M-CS

Assessment of the LOVO device for final harvest of novel cell therapies: a Production Assistance for Cellular Therapies multi-center study

Published Journal Cytotherapy

Share
18 pages Assessment of the LOVO device for final harvest of novel cell therapies: a Production Assistance for Cellular Therapies multi-center study

Overview

This multi-center study compared the LOVO Cell Processing System with routine methods for the final harvest and wash of T cells and mesenchymal stromal cells at four PACT facilities. Viable recovery of tumor-infiltrating lymphocytes was 78.3% on LOVO against 66.7% on Cell Saver 5, with longer run times. The TIL had been expanded in G-Rex®100M-CS flasks.

What this paper found

The LOVO Cell Processing System, which replaces centrifugation with a spinning filtration membrane, gave satisfactory viability and recovery when four NIH-sponsored PACT facilities used it for final harvest or wash of T cells and mesenchymal stromal cells. Each site compared LOVO with its own routine method. For tumor-infiltrating lymphocytes, viable cell recovery was 78.3% on LOVO versus 66.7% on Cell Saver 5. For bone marrow MSCs harvested at Minnesota, viable recovery was 80.0% versus 70.3% on the Cobe 2991. Activated T cell viable recovery was similar (91.1% manual versus 90.4% LOVO), and Miami's post-thaw MSC wash was faster on LOVO (40-45 versus 100 minutes). LOVO took longer at several sites, for example 41 versus 17 minutes for TILs.

Note: Small multicenter study; the authors note that any additional effect of the gentler harvest and wash on cell function remains to be demonstrated.

The LOVO Cell Processing System provides an alternative to centrifuge-based technologies. — Laarni Ibenana, Robert Anderson, Adrian Gee, Margaret Gilbert, Cheryl Cox, Joshua M. Hare, Adriana Brooks, Linda Kelley, Aisha Khan, Natalia Lapteva, Aaron Orozco, David Styers, Darin Sumstad, Ibekwe Ugochi, David H. McKenna, Cytotherapy

Study details

Authors
Laarni Ibenana, Robert Anderson, Adrian Gee, Margaret Gilbert, Cheryl Cox, Joshua M. Hare, Adriana Brooks, Linda Kelley, Aisha Khan, Natalia Lapteva, Aaron Orozco, David Styers, Darin Sumstad, Ibekwe Ugochi, David H. McKenna
Institution
The Emmes Company, LLC, Rockville, MD · Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX · Moffitt Cancer Center, Tampa, FL · Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL · Molecular and Cellular Therapeutics, University of Minnesota, Saint Paul, MN
Journal
Cytotherapy
Year
2022
PMID / PMC
PMID: 35279374 · PMC
G-Rex® model(s)
G-Rex®100, G-Rex®100M-CS
Cell type(s)
Other, T-Cells, TIL Cells
Study phase
Preclinical

How G-Rex® was used

At Baylor, activated T cells from PBMCs activated with anti-CD3/CD28 and IL-7 and IL-15 were expanded in T-75 flasks and then in two G-Rex®100 devices, harvested on days 13 to 21 and pooled. At Moffitt, thawed TIL were seeded at 5×10^6 cells into each of two G-Rex®100M-CS flasks with 400 mL medium, irradiated allogeneic PBMC feeders at 1:200, 6000 IU/mL IL-2 and 30 ng/mL OKT3. Flasks were split to keep 10^6 cells/mL, and about 3 L was harvested on day 14 for the LOVO comparison.

Explore related

Full citation

Ibenana L, Anderson R, Gee A, et al. Assessment of the LOVO device for final harvest of novel cell therapies: a Production Assistance for Cellular Therapies multi-center study. Cytotherapy. 2022;24(7):691-698.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →